Quorum sensing inhibitor-antibiotic conjugate suppresses virulence and eradicates intracellular Staphylococcus aureus.
4 affiliations
- 1Department of Medicinal Chemistry and Pharmaceutical Analysis, School of Pharmacy, Fourth Military Medical University, Xi'an, 710032, PR China.
- 2Department of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, 712046, PR China.
- 3Military Medical Innovation Center, Fourth Military Medical University, Xi'an, 710032, PR China.
- 4Department of Radiation Medical Protection, School of Military Preventive Medicine, Fourth Military Medical University, Xi'an, 710032, PR China.
Abstract
Staphylococcus aureus (S. aureus) employs an array of virulence factors, predominantly governed by the accessory gene regulator (agr) quorum sensing (QS) system, to potentiate infection severity. Particularly challenging is the capacity of intracellular S. aureus to evade both antibiotic treatment and host immune clearance, often resulting in chronic or recurrent infections that complicate pathogen eradication in vivo. To overcome these limitations, we report the rational design of a QS inhibitor-antibiotic conjugate (QSI-A) for simultaneous attenuation of virulence and significant reduction of intracellular S. aureus. This conjugate integrates synthetic autoinducing peptide (AIP) analogues-potent inhibitors of agr QS-with a rifalogue antibiotic via cathepsin-cleavable linkers, supporting intracellular activation within the proteolytic milieu of host cells. Using qRT-PCR, hemolysis assays, and LC-MS, we demonstrate that QSI-A markedly suppresses the expression of key agr components (agrA and RNAIII) and major virulence genes (e.g., psmα, hla, pvl), while substantially reducing δ-toxin production and markedly suppressing hemolytic and cytolytic activities. Mechanistic studies reveal that QSI-A efficiently enters infected host cells-either through direct uptake or co-internalization with bacteria, and undergoes intracellular processing that generates antibacterial activity, leading to effective killing of intracellular S. aureus. In a murine bacteremia model, QSI-A treatment significantly reduced bacterial loads, underscoring its therapeutic potential. These results establish QSI-A as a dual-mechanism anti-infective strategy that concurrently silences virulence expression and targets intracellular reservoirs. Moreover, this QSI-antibiotic conjugate platform holds broad applicability for treating other pathogens dependent on QS-regulated virulence.
Related
- Pseudomonas aeruginosa modulates Staphylococcus aureus biofilm formation and antibiotic resistance
- Aurora A exacerbates antibiotic-resistant Staphylococcus aureus infection through ASC phosphorylation
- A RALGEF inhibitor suppresses lung cancer stem cell development and tumorigenesis
- SD-2102, a Novel PDK1 Inhibitor, Suppresses Lung Cancer Growth by Targeting PDK1/Akt Signaling Pathway
- Aβ42-Driven α-synuclein Fibril Polymorphism and Distinct Intracellular Aggregation
BibTeX
@article{ma2026quorum,
title = {{Quorum sensing inhibitor-antibiotic conjugate suppresses virulence and eradicates intracellular Staphylococcus aureus.}},
author = {Meiling Ma and Shihao Luo and Junshu Wang and Zhuang Nie and Shaonan An and Jianyu Wang and Xiangxiang He and Fei Da and Lin Yao},
journal = {Pharmaceutical science advances},
year = {2026},
month = sep,
doi = {10.1016/j.pscia.2026.100155},
url = {https://europepmc.org/article/MED/42927114},
note = {CC BY},
}
RIS
TY - JOUR
TI - Quorum sensing inhibitor-antibiotic conjugate suppresses virulence and eradicates intracellular Staphylococcus aureus.
AU - Meiling Ma
AU - Shihao Luo
AU - Junshu Wang
AU - Zhuang Nie
AU - Shaonan An
AU - Jianyu Wang
AU - Xiangxiang He
AU - Fei Da
AU - Lin Yao
PY - 2026
DA - 2026/09/28
JO - Pharmaceutical science advances
DO - 10.1016/j.pscia.2026.100155
UR - https://europepmc.org/article/MED/42927114
AB - Staphylococcus aureus (S. aureus) employs an array of virulence factors, predominantly governed by the accessory gene regulator (agr) quorum sensing (QS) system, to potentiate infection severity. Particularly challenging is the capacity of intracellular S. aureus to evade both antibiotic treatment and host immune clearance, often resulting in chronic or recurrent infections that complicate pathogen eradication in vivo. To overcome these limitations, we report the rational design of a QS inhibitor-antibiotic conjugate (QSI-A) for simultaneous attenuation of virulence and significant reduction of intracellular S. aureus. This conjugate integrates synthetic autoinducing peptide (AIP) analogues-potent inhibitors of agr QS-with a rifalogue antibiotic via cathepsin-cleavable linkers, supporting intracellular activation within the proteolytic milieu of host cells. Using qRT-PCR, hemolysis assays, and LC-MS, we demonstrate that QSI-A markedly suppresses the expression of key agr components (agrA and RNAIII) and major virulence genes (e.g., psmα, hla, pvl), while substantially reducing δ-toxin production and markedly suppressing hemolytic and cytolytic activities. Mechanistic studies reveal that QSI-A efficiently enters infected host cells-either through direct uptake or co-internalization with bacteria, and undergoes intracellular processing that generates antibacterial activity, leading to effective killing of intracellular S. aureus. In a murine bacteremia model, QSI-A treatment significantly reduced bacterial loads, underscoring its therapeutic potential. These results establish QSI-A as a dual-mechanism anti-infective strategy that concurrently silences virulence expression and targets intracellular reservoirs. Moreover, this QSI-antibiotic conjugate platform holds broad applicability for treating other pathogens dependent on QS-regulated virulence.
SN - 2773-2169
ER -